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Expanded polytetrafluoroethylene patch 
angioplasty in carotid endarterectomy 
Valentine J. Rhodes, MD, Brick, NJ. 
Purpose: This study retrospectively reviewed the experience with expanded polytetraflu- 
oroethylene ( PTFE) patches for carotid endarterectomy in 924 consecutive procedures 
(753 patients) during a 17-year period. 
2Vlethods: The records of all patients who underwent ePTFE patch angioplasty for carotid 
artery stenosis performed by orte surgeon were reviewed. The eriterion for surgery was 
stenosis of 80% or greater. Follow-up by use of noninvasive methods was done by 6 
months after operation the first year and annuaUy thereafter. Recurrent stenosis was 
confirmed with angiography. Life-table analysis was u ed to estimate the risk ofrestenosis. 
Results: Early morbidity and mortality included six deaths (0.6%), seven onfatal strokes 
(0.9%), and 19 hemorrhages. Two postoperative infections occurred. There were no 
important aneurysmal dilations and no late hemorrhages. With a mean follow-up of 41.4 
months (fange 0 to 197), recurrent stenosis necessitating reoperation developed in 28 
patients (3.7%). There were two late strokes. Life-table analysis indicated a 89% 
probability of freedom from stenosis at 120 months. 
Conclusions: In cases in which the decision to perform patch angioplasty is made at surgery, 
an ePTFE patch is an excellent alternative to autogenous saphenous rein, with a low rate 
ofrecurrences requiring operation and acceptable rates of perioperative and postoperative 
morbidity and mortality. (J VAsc SURG 1995;22:724-31.) 
Carotid endarterectomy has been alternately re- 
garded with caution, enthusiasm, distrust, and then 
renewed enthusiasm after the publication of the 
North American Symptomatic Carotid Endarterec- 
mmy Trial (NASCET)) More recent results from 
the Asymptomatic Carotid Atherosclerosis Study 
(ACAS) 2 have further confirmed the merit ofcarotid 
endarterectomy in the prevention of stroke. Debate 
continues, however, about the value of patch angio- 
plasty for preventing recurrent stenosis and postoper- 
ative thrombosis and the benefits of saphenous vein 
versus ynthetic patches. 
Before 1976, patch angioplasty was performcd 
only in selected cases in our praetice. However, an 
apparently higher ate of recurrent stenosis and peri- 
operative thrombosis in patients having primary clo- 
sure as compared with patch angioplasty prompted 
an increase in the use of patches. Initially, only vein 
From Central Jersey Vascular Specialists, Brick. 
Presented atthe Ninth Annual Meeting of the Eastem Vascular 
Society, May 4-7, 1995, Buffalo, N.Y. 
Reprint requests: Valentine I. Rhodes, MD, Central Jersey 
Vascular Specialists, Inc., Ocean Medical Park, 206 Jack Martin 
Blvd., Brick, New Jersey 08724. 
Copyright © 1995 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/95/$5.00 +  24/6/68964 
724 
patches were used. These appeared to be associated 
with a lower rate of recurrent stenosis than that after 
primary closure, but several of the patches developed 
aneurysmal dilation, and two patients had late disrup- 
tions that required emergency reoperation. These 
problems motivated a switch to cxpanded polytetra- 
fluoroethylene ( PTFE; Gore-tex, W.L. Gore & As- 
sociates, Elkton, Md.) for patch angioplasty, and, 
since 1976, all carotid endarterectomies have been 
performed with this material. The purpose of this 
smdy is to review the outcome with respect o peri- 
operative morbidity and death and postoperative r - 
current stenosis and stroke in a large series ofcarotid 
endarterectomies with ePTFE patch angioplasty. 
MATERIAL AND METHODS 
The records of all patients who tmderwent ePTFE 
patch angioplasty for carotid artery stenosis per- 
formed by one surgeon were reviewed. All proce- 
dures were done between 1976 and 1993. Before 
operation, all patients had stenosis of 80% or greater 
(percentage of vessel diameter), as determined by 
oculopneumoplethysmography (OPG) and echo- 
flow ultrasonography (used from 1976 to 1980), 
spectral frequency analysis or OPG-Gee (1981 to 
1985), or duplex ultrasonography (1985 to 1993), 
and confirmed with angiography. Seventy-six percent 
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Fig. 1. Posterior (A) and lateral (B) views how size, shape, and location ofePTFE patch used 
in carotid endarterectomy. Dotted circle in posterior view represents approximate location of 
orifice of external carotid artery. 
of these patients had symptoms; 24% were symptom 
free. 
Operative teehnique. General endotracheal n- 
esthetic was used in all cases. A crescent-shaped 
incision was made from just below the mastoid 
process down to the cricoid cartilage, at least 1 cm 
beyond the portion of the vessel to be endarterecto- 
mized. This long incision allows mobilization of 
sufficient sternocleidomastoid muscle to obtain wide 
exposure of the carotid artery above and below the 
level of the occluding lesion. The carotid artery was 
skeletonized and looped with vessel loops. Vascular 
clamps were not used because clamp injury may 
increase the risk of subsequent formation of athero- 
matous plaque. In most patients 7500 units of 
intravenous heparin were administered initially, fol- 
lowed by an additional 1000 units per hour. Large 
patients required 10,000 units. Fivc minutes after the 
first administration of heparin, the carotid vessels 
were occluded by placing traction on the vessel loops, 
and a Pruitt-Inahara shunt (Ideas For Medicine, Inc., 
North Clearwater, Fla.) was inserted (except in five 
cases). 
A Freer dissector (Codman Surgical Products, 
Raynharn, Mass.) was used to remove the plaque to 
the adventitial layer. Tacking sutures were placed 
only if the distal intima was nonadherent. Before 
January 1988 the ePTFE pätches were fashioned 
from vascular grafts; since then 0.4 mm ePTFE 
thin-walled cardiovascular patches have becn used. 
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Table I. Patient demographics and risk 
factors for arterial disease 
Mean age (fange) in yr 70.7 (26-90) 
Sex 
Men 417 
Wonnen 336 
Peripheral occlusion or stenosis 333 
Abdominal aortic aneurysm 20 
Myocardial infarction 71 
Previous cartoid endarterectomy 5 
Smoking 551 
Diabetes 241 
Chronic hypertension 521 
Hyperlipidemia 274 
Chronic obstructive pulmonary disease 141 
Polycythemia 10 
The ePTFE patch was trimmed and tapered to the 
appropriate size (approximately 4 mm wide at the 
apex, 7 mm wide at the bulb, and 7 cm long) to 
reconstruct the original shape of the carotid bulb and 
replace at least 50% of the endarterectomized wall of 
the artery, thereby ensuring that less of the throm- 
bogenic arterial surface area was in contact with 
circulating platelets (Fig. 1). 
During the suturing process, the patch was 
stretched to preclude "scalloping" between sutures 
that could result in bleeding. Running sumre was 
used in all cases, with deep bites (1 to 3 mm) taken 
of the arterial wall. The deep bite depth allows 
sculpting of the carotid bulb, thereby helping to 
prevent formation of a dilation. It may also assist in 
preventing suture hole bleeding because the extraar- 
terial tissue is gathered into the suture over the edge 
of the patch. Polypropylene suture material (Prolene; 
Ethicon, Inc., Somerville, N.J. ) was used initially, hut 
ePTFE CV-6 suture (Gore-tex) on a TT-9 needle was 
used exclusively after it became available in January 
1986. Thrombin-soaked oxidized cellulose and digi- 
tal pressure were applied to stop any bleeding before 
closure. Drains were not placed unless the wound 
continued to bleed; in such cases, a Jackson-Pratt 
drain (Baxter Health Care Corp., Deerfield, Ill.) was 
inserted through a separate stab wound. The heparin 
was reversed with 25 to 50 mg of intravenous 
protamine. 
Surveillance protocol. Patients were assessed for 
neurologic symptoms and monitored for recurrent 
stenosis (percentage of vessel diameter) and devel- 
opment of aneurysmal dilation and occlusion with 
noninvasive methods by 6 months after operation the 
first year and annually thereafter, although those with 
evidence of recurrent stenosis were exan~ined more 
offen. OPG with standard criteria and echo-flow 
ultrasonography were used from 1976 to 1980, and 
spectral frequency analysis or Gee-OPG was used 
from 1981 to 1985. In evaluations with spectral 
analysis, any patient having spectral broadening 
consistent with stenosis of 30% or greater was 
considered to have recurrence and was monitored 
more dosely. Duplex ultrasonography began to be 
used in 1985, and color-flow Doppler evaluation was 
added in 1992. 
Angiographic assessment was done in patients in 
whom duplex scanning indicated stenosis of 80% or 
greater and in patients with symptoms of stenosis of 
65% or greater but less than 80% whose symptoms 
did not clear while they were receiving aspirin or 
warfarin therapy and in whom no other canse could 
be identified. Angiography was performed through- 
out the series when the analysis indicated stenosis of 
80% or greater or the patient had development of 
symptoms. Severe recurrent stenosis was confirmed 
at surgery. 
Data analysis. The data were analyzed with re- 
spect o arteries rather than patients at risk. Life-table 
analysis was performed to determine restenosis-free 
survival rates. 
RESULTS 
An ePTFE patch was used to complete 924 
consecutive carotid patch angioplasties in 753 pa- 
tients. The patients' demographic data and risk 
factors for arterial disease on entry into the study are 
provided in Table I. Before operation, contralateral 
carotid artery occlusion was present in 80 patients, 
and contralateral vertebral occlusion was observed in 
13. In 235 patients the contralateral carotid artery 
was normal; in 147 patients taged bilateral endar- 
terectomy was required. The total of 753 patients, 
including the 147 who underwent bilateral proce- 
dures, had 900 initial operations. The additional 24 
ePTFE patch operations in this series were on 20 
patients with recurrent carotid artery stenosis and 4 
with other underlying disease in whom reoperation 
was necessary for stenosis at another site. 
Six (0.6%) patients died during operations, five 
of myocardial infarction and one of stroke. Five 
patients had a nonfatal stroke during surgery. One 
patient had a stroke on the contralateral side 72 hours 
after endarterectomy, and another had a stroke as a 
result of intracranial occlusion (normal results on 
carotid duplex ultrasonography) on the ipsilateral 
side 2 weeks after operation. Therefore the 30-day 
stroke rate was 0.7%. All seven patients recovered 
completely within 2 months. Of the seven nonfatal 
strokes, three were in patients with asymptomatic 
severe stenosis. 
Nineteen patients (1.2%) had perioperative h m- 
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orrhage in the neck requiring reoperation; transfu- 
sions were necessary in six of them. In five of the 19 
(0.5%), the bleeding was from the suture holes in the 
patch in cases in which polypropylene suture had 
been used. Another patient had arterial wall failure, 
and the remalnder had diffuse oozing necessitating 
llgation or cautery ofsmall bleeding sites. There were 
no cases of late postoperative bleeding. 
Two patients had an operative cerebral hemor- 
rhage. One had a complete and the other a partial 
recovery. Four patients had severe suture line failure 
requiring reoperation within 72 hours of surgery; the 
failure was due to breakage of the polypropylene 
suture in two cases and arterial wall failure in the 
others. Three patients had perioperative transient 
ischemic attacks (TIAs). These occurred immediately 
after surgery in one patient, 2 weeks after operation 
in another, and 3 weeks after operation in the third. 
All three patients had normal results on duplex 
scanning or angiography. Three cases of cerebral 
edema occurred in the immediate postoperative 
period. The edema resolved, and the patients recov- 
ered completely. 
Infection occurred in two patients (0.2%). One 
was treated with removal of the ePTFE patch and 
implantation of a new one and the other with removal 
of the prosthesis and replacement with an autog- 
enous rein patch. Both patients also received systemic 
and topical antibiotic therapy. The infections re- 
solved without further sequelae, and both patients 
remained weil during the follow-up period. 
Follow-up averaged 41.4 months (range 0 to 
197). Detectable recurrent stenosis developed in 84 
patients (8.9%); 42 (4.5%) had less than 50% 
stenosis, and 19 (2.0%) had 50% to 65% stenosis. In 
10 of these 19, the stenosis ubsequently progressed 
by about 10% during the first year. None of the 
patients with recurrent stenosis ofless than 80% had 
symptoms. Recurrent stenosis of 80% or greater 
developed, and reoperation was necessary in 28 
patients (3.7%). Because two of these 28 patients had 
bilateral recurrence, and three had two recurrences on 
the same side, 33 reoperations were performed as a 
result of recurrence. Of these, 23 (70%) were in 
patients with symptoms (ipsilateral TIAs), and 10 
(30%) were performed in symptom-free patients. At 
surgery the only patent portion of the lumen in 
several of the arteries operated on was a slit under the 
patch; the remainder of the lumen was obliterated by 
fibrous tissue. 
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Table II. Recurrent carotid artery stenosis after carotid endarterectomy with ePTFE patch 
Arteries with restenosis 
Interval (mo.) No. at ~isk »_ 80% ~ No. lost to evaluation~ Recurrence free (% ± SE) 
0-1 924 1 40 100 _+ 0 
1-3 883 2 30 99.9 ± 0.1 
3-9 851 3 115 99.7 ± 0.2 
9-12 733 4 24 99.3 ± 0.3 
12-24 705 6 146 98.7 ± 0.4 
24-36 553 6 117 97.8 -+ 0.5 
36-48 430 2 112 96.6 ± 0.7 
48-60 316 2 90 96.1 _+ 0.8 
60-72 224 2 70 95.4 ± 0.9 
72-84 152 3 35 94.4 ± 1,2 
84-96 114 0 34 92.3 ± 1,7 
96-108 80 1 23 92.3 ± 1,7 
108-120 56 1 18 90.9 -+ 2,1 
> 120 37 0 37 89.0 ± 2,8 
~In 28 patients. 
?ßecause of death, loss to follow-up, infection, reoperation ot caused by recurrence, or end of  smdy. 
All recurrent stenoses were observed within 114 
months, and all but five appeared within 73 months. 
At 5 years there were 26 hemodynamicaUy important 
recurrent stenoses (3.0%). Freedom from stenosis as 
determined by life-table analysis is shown in Fig. 2 
and Table II. At last follow-up the probability of 
freedom from stenosis was 89%. 
There were two late strokes. One occurred in the 
patient who had a postoperative infection and 
replacement of the ePTFE patch with a vein patch. 
The stroke occurred on the ipsilateral side 5 years 
after surgery. The patient's condition stabilized with 
a 3% to 5% deficient in the upper limb on the side 
affected. The other stroke, also ipsilateral, occurred 
about 8 years after operation; the patient underwent 
reoperation and had a complete recovery by 6 months 
after the surgery. Throughout he series there were 
no late occlusions of the ePTFE patch graft and no 
late TIAs referable to the ipsilateral carotid artery 
territory and not included in the recurrent stenosis 
group. 
Before duplex scanning became available, angi- 
ography performed in patients with symptoms or 
recurrence on spectral analysis found no clinically 
important aneurysms. Duplex scanning has revealed 
some minor dilations in carotid bulbs, but none were 
considered to have clinical implications. 
DISCUSSION 
The publication of the North American Symp- 
tomatic Carotid Endarterectomy Trial, ~ the Asymp- 
tomatic Carotid Atherosclerosis Study ,  2 and the 
American Heart Association's guidelines for carotid 
endarterectomy 4 have clarified the indications for 
carotid artery surgery and eliminated some of the 
controversy urrotmding the procedure. On the other 
hand, the debate on the value of primary approxi- 
mation versus patch angioplasty in preventing recur- 
rent carotid artery stenosis continues, especially 
because recurrence has been observed more fre- 
quently since noninvasive imaging techniques such as 
duplex scanning became widely available. Although 
only 20% to 25% of cases of recurrent stenosis will 
progress to manifestation of neurologic symptoms, 
the disorder remains an important cause of late 
morbidity and death.s 
Several studies have demonstrated that the use of 
a patch in carotid endarterectomy significantly lowers 
the rate of recurrent stenosis, 8 and the 2.4% 
incidence ofsevere recurrent stenosis ( _> 80%) in this 
series ofpatch angioplasties supports those results. In 
attempting to explain the antirestenosis effect of 
patches, Deriu et al. 9 speculated that enlarging the 
lumen retards the development of intimal lesions. 
Zierler et al. 10 theorized that a patch favorably affects 
hemodynamic flow by altering the geometric on- 
figuration and compliance of the carotid bulb. 
Increasing the circumference of the lumen may also 
play a part. 
Interestingly, a multicenter study comparing the 
incidence of recurrent stenosis after balloon angio- 
plasty and stent deployment in the coronary arteries 
found that the most accurate predictor of restenosis 
was the minimal lumen diameter immediately after 
the procedure, regardless of the type of intervention 
used. n It is theoretically possible that similar reste- 
nosis mechanisms are at work in the carotid artery 
system and that enlarging file arterial umen with a 
patch may not prevent he development of intimal 
hyperplasia per se but may keep the vessel from 
narrowing to the point of becoming stenotic. ~2 
Although patch angioplasty has been found to be 
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beneficial in preventing restenosis, many authors till 
consider it appropriate only in women, patients with 
a history of smoking, or patients with peripheral 
arterial insufficiency or small arteries.la'14 Ten Holter 
et al., e however, have reported that patching signifi- 
cantly reduced the incidence of restenosis n men and 
women. 
Once the decision to perform patch angioplasty 
has been made, the surgeon must decide whether to 
use a vein patch or a synthetic material. The most 
important disadvantage of saphenous vein patches is 
the irregularity of their mechanical integrity, which 
varies according to the site of harvest 14 and may pre- 
dispose them to aneurysmal dilation and disruption. 
In contrast, ePTFE has high tensile strength, 15,16 
which may make it more resistant o the hemody- 
namic forces accompanying an increased lumen di- 
ameter and less likely to dilate or disrupt. This series 
of 924 cases had no clinically important aneurysmal 
dilations and no disruptions. A synthetic patch also 
offers the advantage of saving the saphenous vein for 
arterial reconstructions or bypass grafting that might 
subsequently become necessary. 
Another consideration i  patching is the width of 
the material. Fietsam et a1.17 support primary closure 
or the use of a narrow patch that closely approximates 
the original arterial diameter because of their experi- 
mental data indicating that this produces less hemo- 
dynamic instability and flow separation and their 
belief that these factors contribute to restenosis. On 
the other hand, clinical studies have shown that 
primary closure appears to contribute to subsequent 
arterial narrowing. 5-7 It may be that an appropriately 
sized ePTFE patch placed over the carotid bulb 
causes the reversed flow to occur over the patch rather 
than the endarterectomized portion of the artery, 
thereby exposing the native vessel to fewer circulating 
platelets that could form aggregates and subsequent 
thrombosis and late stenosis. A narrow patch would 
not replace nough of the rough endarterectomized 
arterial surface with the less thrombogenic ePTFE 
surface to avoid such aggregation. In this series, all 
patches were sized to replace 50% or more of the 
endarterectomized wall of the artery. 
Operative needle hole or late postoperative bleed- 
ing has been reported with the use of ePTFE carotid 
artery patches) 8-2° These occurrences have generally 
been related to the use of needle/suture combinations 
in which the needle is larger in diameter than the 
suture, so that the suture does not completely fill the 
hole made in the patch by the needle. In other studies 
of the use of ePTFE in carotid endarterectomy, 13,2~ 
no bleeding problems have been observed. Reduc- 
tion of blood loss has been found to be associated 
with a needle/suture diameter ratio of 1:1, 22 and the 
ePTFE suture we use has such a ratio. Wc believe that 
the needle/suture combination we use, along with the 
routine use of a heparin reversal protocol, 23 contrib- 
uted to the absence of important operative and any 
late postoperative bleeding in this series. 
Although this series did not involve a randomized 
study of patching compared with primary approxi- 
mation or vcin patching versus ynthetic patching, its 
consistently excellent results indicate that if the 
decision to perform patch angioplasty is made at 
surgery, ePTFE is an excellent alternative to autog- 
enous saphenous vein, with a low rate of recurrences 
that require reoperation, minimal aneurysmal dila- 
tion, and acceptable perioperative and postoperative 
morbidity and mortality rates. 
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DISCUSSION 
Dr. Harry L. Bush, Jr. (New York, N.Y.). Dr. Rhodes 
has reported an operative mortality rate of approximately 
0.6% and a perioperative stroke rate of less than 1%, both 
of which are clearly significantly lower than the kind of 
outcomes that have been suggested by numerous national 
and interdisciplinary groups in terms of carotid artery 
surgery. Obviously this experience goes back a way and 
spans the time interval that most of these controversies 
were being raised across the country. Certainly these 
excellent results demonstrate the safety and durability of the 
operation when the patients are properly selected and the 
surgery is performed expertly. 
It's a personal decision whether to patch or use primary 
closure, and, for many people, selective use of the patch 
where you have a difficult end point or a small internal 
carotid artery or an unusually long endarterectomy is 
certainly a clear indication for some people to use the 
selective approach to patch angioplasty. 
It's not clear in terms of national experience that there 
has been a clear benefit shown to use a routine patch, and 
this is obviously adecision that most of us have to make on 
the basis of our own experience and the environment that 
we work in. Have you ever considered taking a more 
selective approach and foregoing what for you has been an 
excellent technique? Has the extra time that it takes to do 
the sumring for the pätch or the extra time required for use 
of the shunt ever made you reconsider the possibility of 
selectively using the patch and therefore the shunt? 
Once a decision has been made to patch, the hext 
question obviously is what material to use for the patch 
angioplasty, and you'll find advocates for the use of the 
proximal or distal portion of the greater saphenous rein, for 
use of cervical veins, and for use of Dacron and PTFE. I find 
that use of the spatulated portion of the external jugular 
rein provides avery durable material for this, although this 
would be at best controversial. However, most of the 
questions come to mind about the use of the prosthetic 
material. 
One of the complications for which you've evolved 
your technique relates to bleeding. People have reported 
both early and late bleeding complications, and you seem 
to have had an appropriate l vel for both ofthose. How did 
you evolve your difference in the use of suture material in 
relation to needle hole bleeding? What material are you 
using for your patch, are you using the 0.4 or 0.6 
cardiovascular patch, or are you taking an existing raft that 
has a thicker wall and has been shown to have less difficulty 
with the needle hole bleeding? Conversely, it's also harder 
to ger the sutures to go through it. 
I gather there was really no incidence of acute 
thrombosis in this group of patients, or at least that 
couldn't be identified immediately and rectified at that 
time. 
Now, one of the other things that comes to mind is that 
one of the reasons that people advocate use of the patch is 
to decrease reoperations. Do you believe that your need for 
reoperation i these patients could be related to the routine 
use of the patch material? Is there anything about the 
healing of this kind of patch that increases the risk for 
thromboembolic or recurrent disease? 
Dr. Valentine J. Rhodes. The decision whether to 
patch is an individual one. For me it has worked. I perform 
patch angioplasty on all of my patients because Fm more 
comfortable with it. 
In the very early days (1969 to 1976), I performed 
straight endarterectomies followed by vein patching fol- 
lowed by Dacron, but Dacron in those days was a little 
different than Dacron today, and I wasn't happy with it. It's 
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true when I used to cut up the old grafts I didn't have any 
bleeding problem regardless of the kind of suture I used, 
bnt I've been using the 0.4 cardiovascular carotid artery 
patches ince they first came out. 
That's when I had to use the 6-0 one on a TF9 needle. 
I noticed that if I even used a PT9, which is the cutting tip 
needle, that there was too much bleeding from the suture 
holes to satisfy me, and if I used polypropylene there was 
excessive bleeding from the suture holes. And that's when 
I checked and found that there is a discrepancy in the 
diameter of the sumre versus the needle with polypropylene 
and some of the other sutures. And when I looked at the 
literature, I noticed that most of the people who were 
commenting on excessive bleeding from the needle holes 
were using much larger needles. 
One example was the use of a TH13 piercing tip needle, 
which is the cutting edge on a 7-0 sumre. This needle 
diameter is significantly larger than that of the suture and 
there were probably aseries of fountains of blood. And it's 
true, the cardiovascular patch is much less forgiving as rar 
as bleeding from the suture holes than a vein would be or 
a straight endarterectomy, of conrse. I can't comment on 
Dacron because I have no experience with modern Dacron 
used as a patch on a carotid artery. 
In my experience, the patch gave me better esults, so 
that's why I've stayed with it. I had three incidents of acute 
thromboses. In one situation, the patient woke up and was 
fine. While the patient was being transferred to the 
stretcher, weakness in the arm started to develop. I 
immediately had the patient reanesthetized. The patient 
was still intubated. I performed a thrombectomy, and that 
patient had no neurologic deficit. The other two incidents 
occurred in the recovery room in the days before I started 
resecting kinks. These are listed under the acute strokes, and 
what I found was that the patch made the artery stift, and 
with the systolic thrust the artery was driven forward 
against he kink and thrombosed. I believe that was the 
cause, and that's what started me resecting aH kinks. I don't 
know whether that's a valid assumption, but that's when I 
started resecting all the kinks. There have been no acute 
thromboses in the last 380. 
The 5-year ecurrence rate was 1.6% in the total group. 
Now most of the series are talking about 5-year ecurrence 
rates. When I continued the follow-up beyond 5 years, I
started seeing the atherosclerotic recurrences and they're 
calculated in the graft. But the recurrence rate at the first 5 
years was 1.6%. 
Dr. Robert W. Hobson I I  (Newark, N.J.). Some 
surgeons advocate the use of autologous patch material. I 
want to ask Dr. Dardik to comment on his advocacy for 
autologous patches from cervical veins. Does choice of 
synthetic versus autologous patches make a difference in 
the final analysis? 
Dr. Herbert  Dardik (Englewood, NJ.) .  We are in 
the midst ofa comparative study that includes cervical and 
saphenous veins, infrequently prosthetic material. In my 
view, the results are comparable for all materials o that 
what you use matters little. My first choice of patch ma- 
terial is everted cervical vein; prosthetics, especially 
glutaraldehyde-processed bovine pericardium and then 
other prosthetics are my second choices, followed by au- 
tologous aphenous vein. There is a theoretical dvantage 
for autologous vein, but I remain unconvinced that it really 
is so in a practical sense. 
Dr. Hobson. The well-done patch is probably inde- 
pendent of the material in the absence of complications 
such as in infection. Dr. Rhodes,I noticed that your figures 
emphasized a relatively narrow patch avoiding the bulging 
patch. 
Dr. Rhodes. I use a wide patch, but I also use large 
enough suture bites on the endarterectomized wall of the 
bulb to reduce the diameter of the arterial wall to the 
amount of the patch diameter, so that the patch replaces 
50% of the original bulb diameter but does not increase the 
bulb diameter. I try to replace 50% of the bulb with patch. 
I f I  have a large bulb to begin with, I'll trim it so that I can 
replace it with more patch. 
